The lower in vitro chondrogenic potential of canine adipose tissue-derived mesenchymal stromal cells (MSC) compared to bone marrow-derived MSC is not improved by BMP-2 or BMP-6

M Teunissen; F Verseijden; FM Riemers; Gerjo van Osch; MA Tryfonidou

doi:10.1016/j.tvjl.2020.105605

The lower in vitro chondrogenic potential of canine adipose tissue-derived mesenchymal stromal cells (MSC) compared to bone marrow-derived MSC is not improved by BMP-2 or BMP-6

M Teunissen, F Verseijden, FM Riemers, Gerjo van Osch, MA Tryfonidou

Research output: Contribution to journal › Article › Academic › peer-review

16 Citations (Scopus)

8 Downloads (Pure)

Abstract

Mesenchymal stromal cells (MSC) are used for cell-based treatment for canine osteoarthritis (OA). Compared with human MSCs, detailed information on the functional characterisation of canine MSCs is limited. In particular, the chondrogenic differentiation of canine adipose tissue-derived MSCs (cAT-MSCs) is challenging. In this study, we aimed to compare cAT-MSCs with bone marrow-derived MSCs (cBM-MSCs), focusing specifically on their in vitro chondrogenic potential, with or without bone morphogenetic proteins (BMP). cBM-MSCs and cAT-MSCs were characterised using flow cytometry and reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The chondrogenic differentiation potential of all cMSC preparations in the presence of TGF-β1 alone or when supplemented with 10, 100, or 250 ng/mL BMP-2 or BMP-6 was investigated using RT-qPCR, and biochemical, histochemical and immunohistological analyses. Both cBM-MSCs and cAT-MSCs expressed the surface markers CD90, CD73, and CD29, and were negative for CD45 and CD34, although the expression of CD73 and CD271 varied with donor and tissue origin. Interestingly, expression of ACAN and SOX9 was higher in cBM-MSCs than cAT-MSCs. In contrast with cBM-MSCs, cAT-MSCs could not differentiate toward the chondrogenic lineage without BMP-2/-6, and their in vitro chondrogenesis was inferior to cBM-MSCs with BMP-2/-6. Thus, cAT-MSCs have lower in vitro chondrogenic capacity than cBM-MSC under the studied culture conditions with 10, 100, or 250 ng/mL BMP-2 or BMP-6. Therefore, further characterisation is necessary to explore the potential of cAT-MSCs for cell-based OA treatments.

Original language	English
Article number	105605
Journal	Veterinary Journal
Volume	269
DOIs	https://doi.org/10.1016/j.tvjl.2020.105605
Publication status	Published - Mar 2021

Bibliographical note

Funding Information:
This work was supported by the AO Bone ( S-10-48T ) and the Dutch Arthritis Society ( LLP22 ). We thank Harry van Engelen for providing assistance with the collection of the tissue samples, Ger Arkenstein for aiding with the FACS analysis, and Karin Benz for gifting BMP-2 generously. Preliminary results were presented as a poster at the first MBE (Matrix Biology Europe) conference, Rotterdam, 21–24 June 2014.

Publisher Copyright:
© 2021 The Authors

Research programs

EMC OR-01

Access to Document

10.1016/j.tvjl.2020.105605Licence: CC BY-NC-ND

Repub_133436_O-A.pdfFinal published version, 1.57 MB

https://dspace.library.uu.nl/bitstream/handle/1874/411719/1_s2.0_S1090023320301829_main.pdf?sequence=1&isAllowed=yLicence: CC BY-NC-ND

Cite this

@article{e74a6cad82244313aa5bf798fca3fd8e,

title = "The lower in vitro chondrogenic potential of canine adipose tissue-derived mesenchymal stromal cells (MSC) compared to bone marrow-derived MSC is not improved by BMP-2 or BMP-6",

abstract = "Mesenchymal stromal cells (MSC) are used for cell-based treatment for canine osteoarthritis (OA). Compared with human MSCs, detailed information on the functional characterisation of canine MSCs is limited. In particular, the chondrogenic differentiation of canine adipose tissue-derived MSCs (cAT-MSCs) is challenging. In this study, we aimed to compare cAT-MSCs with bone marrow-derived MSCs (cBM-MSCs), focusing specifically on their in vitro chondrogenic potential, with or without bone morphogenetic proteins (BMP). cBM-MSCs and cAT-MSCs were characterised using flow cytometry and reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The chondrogenic differentiation potential of all cMSC preparations in the presence of TGF-β1 alone or when supplemented with 10, 100, or 250 ng/mL BMP-2 or BMP-6 was investigated using RT-qPCR, and biochemical, histochemical and immunohistological analyses. Both cBM-MSCs and cAT-MSCs expressed the surface markers CD90, CD73, and CD29, and were negative for CD45 and CD34, although the expression of CD73 and CD271 varied with donor and tissue origin. Interestingly, expression of ACAN and SOX9 was higher in cBM-MSCs than cAT-MSCs. In contrast with cBM-MSCs, cAT-MSCs could not differentiate toward the chondrogenic lineage without BMP-2/-6, and their in vitro chondrogenesis was inferior to cBM-MSCs with BMP-2/-6. Thus, cAT-MSCs have lower in vitro chondrogenic capacity than cBM-MSC under the studied culture conditions with 10, 100, or 250 ng/mL BMP-2 or BMP-6. Therefore, further characterisation is necessary to explore the potential of cAT-MSCs for cell-based OA treatments.",

author = "M Teunissen and F Verseijden and FM Riemers and {van Osch}, Gerjo and MA Tryfonidou",

note = "Funding Information: This work was supported by the AO Bone ( S-10-48T ) and the Dutch Arthritis Society ( LLP22 ). We thank Harry van Engelen for providing assistance with the collection of the tissue samples, Ger Arkenstein for aiding with the FACS analysis, and Karin Benz for gifting BMP-2 generously. Preliminary results were presented as a poster at the first MBE (Matrix Biology Europe) conference, Rotterdam, 21–24 June 2014. Publisher Copyright: {\textcopyright} 2021 The Authors",

year = "2021",

month = mar,

doi = "10.1016/j.tvjl.2020.105605",

language = "English",

volume = "269",

journal = "Veterinary Journal",

issn = "1090-0233",

publisher = "Bailliere Tindall Ltd",

}

TY - JOUR

T1 - The lower in vitro chondrogenic potential of canine adipose tissue-derived mesenchymal stromal cells (MSC) compared to bone marrow-derived MSC is not improved by BMP-2 or BMP-6

AU - Teunissen, M

AU - Verseijden, F

AU - Riemers, FM

AU - van Osch, Gerjo

AU - Tryfonidou, MA

N1 - Funding Information: This work was supported by the AO Bone ( S-10-48T ) and the Dutch Arthritis Society ( LLP22 ). We thank Harry van Engelen for providing assistance with the collection of the tissue samples, Ger Arkenstein for aiding with the FACS analysis, and Karin Benz for gifting BMP-2 generously. Preliminary results were presented as a poster at the first MBE (Matrix Biology Europe) conference, Rotterdam, 21–24 June 2014. Publisher Copyright: © 2021 The Authors

PY - 2021/3

Y1 - 2021/3

N2 - Mesenchymal stromal cells (MSC) are used for cell-based treatment for canine osteoarthritis (OA). Compared with human MSCs, detailed information on the functional characterisation of canine MSCs is limited. In particular, the chondrogenic differentiation of canine adipose tissue-derived MSCs (cAT-MSCs) is challenging. In this study, we aimed to compare cAT-MSCs with bone marrow-derived MSCs (cBM-MSCs), focusing specifically on their in vitro chondrogenic potential, with or without bone morphogenetic proteins (BMP). cBM-MSCs and cAT-MSCs were characterised using flow cytometry and reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The chondrogenic differentiation potential of all cMSC preparations in the presence of TGF-β1 alone or when supplemented with 10, 100, or 250 ng/mL BMP-2 or BMP-6 was investigated using RT-qPCR, and biochemical, histochemical and immunohistological analyses. Both cBM-MSCs and cAT-MSCs expressed the surface markers CD90, CD73, and CD29, and were negative for CD45 and CD34, although the expression of CD73 and CD271 varied with donor and tissue origin. Interestingly, expression of ACAN and SOX9 was higher in cBM-MSCs than cAT-MSCs. In contrast with cBM-MSCs, cAT-MSCs could not differentiate toward the chondrogenic lineage without BMP-2/-6, and their in vitro chondrogenesis was inferior to cBM-MSCs with BMP-2/-6. Thus, cAT-MSCs have lower in vitro chondrogenic capacity than cBM-MSC under the studied culture conditions with 10, 100, or 250 ng/mL BMP-2 or BMP-6. Therefore, further characterisation is necessary to explore the potential of cAT-MSCs for cell-based OA treatments.

AB - Mesenchymal stromal cells (MSC) are used for cell-based treatment for canine osteoarthritis (OA). Compared with human MSCs, detailed information on the functional characterisation of canine MSCs is limited. In particular, the chondrogenic differentiation of canine adipose tissue-derived MSCs (cAT-MSCs) is challenging. In this study, we aimed to compare cAT-MSCs with bone marrow-derived MSCs (cBM-MSCs), focusing specifically on their in vitro chondrogenic potential, with or without bone morphogenetic proteins (BMP). cBM-MSCs and cAT-MSCs were characterised using flow cytometry and reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The chondrogenic differentiation potential of all cMSC preparations in the presence of TGF-β1 alone or when supplemented with 10, 100, or 250 ng/mL BMP-2 or BMP-6 was investigated using RT-qPCR, and biochemical, histochemical and immunohistological analyses. Both cBM-MSCs and cAT-MSCs expressed the surface markers CD90, CD73, and CD29, and were negative for CD45 and CD34, although the expression of CD73 and CD271 varied with donor and tissue origin. Interestingly, expression of ACAN and SOX9 was higher in cBM-MSCs than cAT-MSCs. In contrast with cBM-MSCs, cAT-MSCs could not differentiate toward the chondrogenic lineage without BMP-2/-6, and their in vitro chondrogenesis was inferior to cBM-MSCs with BMP-2/-6. Thus, cAT-MSCs have lower in vitro chondrogenic capacity than cBM-MSC under the studied culture conditions with 10, 100, or 250 ng/mL BMP-2 or BMP-6. Therefore, further characterisation is necessary to explore the potential of cAT-MSCs for cell-based OA treatments.

UR - http://www.scopus.com/inward/record.url?scp=85099242182&partnerID=8YFLogxK

U2 - 10.1016/j.tvjl.2020.105605

DO - 10.1016/j.tvjl.2020.105605

M3 - Article

C2 - 33593496

SN - 1090-0233

VL - 269

JO - Veterinary Journal

JF - Veterinary Journal

M1 - 105605

ER -

The lower in vitro chondrogenic potential of canine adipose tissue-derived mesenchymal stromal cells (MSC) compared to bone marrow-derived MSC is not improved by BMP-2 or BMP-6

Abstract

Bibliographical note

Research programs

Access to Document

Other files and links

Fingerprint

Cite this